

2. Baseline Characteristics

Table 1: Baseline (time one) characteristics of sample

Variable	Control			Delaye	d intervei	ntion	Intervention	with no	booster	Intervention with booster			
	mean	SD	N	mean	SD	N	mean	SD	N	mean	SD	N	
Demographic													
Ethnicity													
White British			16			21			12			15	
Other			3			4			2			0	
Gender													
Female			16			19			13			14	
Male			4			6			1			1	
Age	58.22	13.10	18	59.33	13.84	24	60.79	13.36	14	61.17	11.67	12	
BMI	33.1	5.49	18	33.86	5.48	24	29.99	3.75	14	32.02	4.74	12	
Waist circumference	45.18	12.36	18	51.98	27.81	24	47.42	18.67	14	50.85	21.77	12	
Other variables													
Action control	4.41	1.48	20	4.05	1.37	26	4.12	1.55	14	3.71	1.59	15	
Self reported habit index	5.09	1.66	20	4.32	1.80	26	4.20	1.59	14	4.57	1.79	15	

3. Outcome Measures

Table 2: Outcomes at time two (4-5 weeks into intervention)

Variable	Control			Delayed intervention			Intervention with no booster				Intervention with booster			
	mean	SD	N	mean	SD	N	mean	SD	N		mean	SD	N	
Action control	4.12	1.33	13	4.75	1.36	18	4.69	1.55	8		4.56	1.97	8	
Self reported habit index	3.44	1.74	13	3.83	1.95	18	3.88	1.70	8		3.91	1.49	8	

Table 3: Outcomes at time three (8-10 weeks at end of intervention)

Variable	Control			Delayed intervention			Intervention with no booster			Intervention with booster		
	mean	SD	N	mean	SD	N	mean	SD	N	mean	SD	N
BMI	32.77	5.90	19	33.14	5.73	20	30.08	3.25	14	31.85	5.01	12
Waist circumference	43.34	12.82	16	54.63	31.57	17	46.42	18.47	13	52.80	24.09	5
Action control	3.76	1.46	14	4.35	1.57	16	5.06	1.30	9	4.31	1.77	6
Self reported habit index	3.59	1.79	14	3.88	2.09	16	3.39	1.63	9	2.25	.76	6

Table 4: Outcomes at time four (3 months after intervention)

Variable	Control			Delayed intervention			Intervention	n with no	booster	Intervention with booster			
	mean	SD	N	mean	SD	N	mean	SD	N	mean	SD	N	
BMI	32.41	6.11	16	32.47	4.91	18	29.70	3.39	12	31.39	4.89	9	
Waist circumference	43.97	14.23	13	56.03	33.40	15	47.41	20.43	11	49.42	22.91	6	

4. Adverse Events

No adverse events were associated with this trial.